Last update 07 Mar 2026

Calgent Biotechnology Co. Ltd.

Private Company|2019|Taiwan Province, China|
< 10
|
www.calgent.com

Overview

Tags

Neoplasms
Digestive System Disorders
Immune System Diseases
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases3
Neoplasms2
Endocrinology and Metabolic Disease2
Hemic and Lymphatic Diseases1
Top 5 Drug TypeCount
Small molecule drug5
Chemical drugs1
Top 5 TargetCount
Ubiquitin ligase(E3 ubiquitin ligase components)2
ITCH(itchy E3 ubiquitin protein ligase)1

Related

6
Drugs associated with Calgent Biotechnology Co. Ltd.
Fiberfate
Target
Ubiquitin ligase
Mechanism
Ubiquitin ligase inhibitors
Active Org.
Calgent Biotechnology Co. Ltd.
Originator Org.
Calgent Biotechnology Co. Ltd.
Active Indication
Pulmonary Fibrosis
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Hectinib
Target
Ubiquitin ligase
Mechanism
Ubiquitin ligase inhibitors
Active Org.
Calgent Biotechnology Co. Ltd.
Originator Org.
Calgent Biotechnology Co. Ltd.
Active Indication
Colorectal Cancer [+3]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
CAL-010
Target-
Mechanism-
Active Org.
Calgent Biotechnology Co. Ltd.
Originator Org.
Calgent Biotechnology Co. Ltd.
Active Indication
Obesity
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Calgent Biotechnology Co. Ltd.
NCT04686383
/ CompletedPhase 1
A Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Solid Tumors Resistant or Refractory to Standard Treatments
100 Clinical Results associated with Calgent Biotechnology Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Calgent Biotechnology Co. Ltd.
Login to view more data
3
News (Medical) associated with Calgent Biotechnology Co. Ltd.
10 Jun 2025
CAL056 (Hectinib) - Calgent Biotechnology Co. Ltd. | Novel Drugs | Unmet Medical Needs
Orphan Drug
07 Sep 2022
【2022/6/13】BIO International Convention (US BIO 2022)
09 Feb 2021
【2021/2/9】CAL056 received TFDA approval of Phase I
Phase 1IND
100 Deals associated with Calgent Biotechnology Co. Ltd.
Login to view more data
100 Translational Medicine associated with Calgent Biotechnology Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
4
2
Phase 1
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Hectinib
 ( Ubiquitin ligase )		Non-Small Cell Lung Cancer
More
Phase 1
Fiberfate
 ( Ubiquitin ligase )		Pulmonary Fibrosis
More
Phase 1
MPT0L056
 ( ITCH )		Neoplasms
More
Preclinical
CAL-010
Obesity
More
Preclinical
CAL-005
Colonic Cancer
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free